ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Clinical, microbiological, and molecular characteristics, outcomes, and risk factors for mortality of patients with Stenotrophomonas maltophilia bloodstream infection.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to explore the clinical, microbiological, and molecular characteristics of Stenotrophomonas maltophilia bacteraemia, outcomes, and risk factors associated with mortality.
methodsThis was a nationwide retrospective cohort study of patients with S. maltophilia bacteraemia during the period between January 2017 and December 2021. MIC Test Strips (Liofilchem, Roseto degli Abruzzi, Italy) were used for susceptibility testing, and Illumina for whole genome sequencing. Kaplan-Meier survival analysis and a multivariable Cox regression model were utilized to assess independent predictors of 90-day all-cause mortality.
resultsNinety patients were included, with a median age of 51.5 years (IQR 37-61), and 25.6% were females. The most common underlying medical conditions included diabetes mellitus (42.2%), and haematological malignancy (23.3%); and 64.4% were immunosuppressed. The most common sources of bacteraemia were the respiratory tract (38.9%) and vascular lines (25.6%). In vitro susceptibility rates were highest for trimethoprim-sulfamethoxazole (98.9%), and levofloxacin (61.1%). Sequencing demonstrated extensive genomic heterogeneity, and sul1 gene was detected in only one strain. The most frequent therapy was trimethoprim-sulfamethoxazole, monotherapy (77.8%) or in combinations (6.7%), for a median duration of 10 days (IQR 5-14). All-cause 90-day mortality was 44.4%. Receiving trimethoprim-sulfamethoxazole was associated with improved 90-day survival (log-rank P < 0.001), and was independently associated with lower mortality in the multivariable Cox model (hazard ratio 0.21, 95% confidence interval 0.06 to 0.74).
conclusionS. maltophilia blood isolates are genomically diverse and remain mostly susceptible to trimethoprim-sulfamethoxazole. Using trimethoprim-sulfamethoxazole for patients with S. maltophilia bacteraemia appears to be associated with improved survival.
Indexed as
Identifiers
42611349What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.